CureVac shares surge after preliminary data on COVID-19 and flu shots

CureVac
CVAC,
+29.47%
shares rocketed 26% in premarket trade, extending Friday’s gains after the German company said preliminary data from its early stage trial for its COVID-19 and seasonal flu shots had positive results to advance to the next stage of clinical testing. CureVac is developing the shots with GlaxoSmithKline
GSK,
+1.28%
GSK,
-0.91%.
CureVac said the COVID-19 shot was well tolerated, and that neutralizing antibodies were beginning at the lowest tested dose for younger adults. The seasonal flu shot was also well tolerated with an increase in antibodies compared to those from a flu vaccine comparator in younger adults, CureVac said. CureVac had gained 29% on Friday.